# NHS Framework Agreement for the supply of Icatibant and C1 Esterase products for the treatment of Hereditary Angioedema

> Contract award record from UK public-sector procurement sources.

## Key facts

- Public buyer: [NHS England](/buyers/nhs-england/contract-awards)
- Contract winner: Shire Pharmaceuticals Ltd
- Award value: £72,000,000
- Tender value: £72,000,000
- Award date: 20 June 2018
- Published: 16 July 2018
- Contract start: 1 July 2018
- Contract end: 30 June 2019
- Stage: awarded
- Procurement category: goods
- Notice ID: 7400eba6-8e62-4241-879e-a0c574ef4408-229021
- OCID: ocds-b5fd17-1d6a380a-446a-4d72-ac49-db35a20e38a5

## Description

NHS Framework Agreement for the supply of Icatibant and C1-Esterase products for the treatment of Hereditary Angioedema\. The framework will commence on 1st July 2018 for a period of 12 months until 30th June 2019, with options to extend up to a further 36 months\.

## Related contract awards

- [Transformation Delivery Services - Establishing Operational Excellence \(EOE\)](/contracts/ocds-b5fd17-b08595d2-8961-409b-9b62-7b01d7a64541): NHS England
- [Identity Access Management - Service Adoption and Enablement](/contracts/ocds-b5fd17-08ebad6c-84fb-4e62-9afd-d06d220dd3a5): NHS England
- [OutSystems licenses for MAPPTI \(AP&P\)](/contracts/ocds-b5fd17-521fbf90-6e93-4366-b3bc-47aa2efd447d): NHS England
- [Recombinant Von Willebrand Factor](/contracts/ocds-b5fd17-73c7f75a-2d95-4205-9a33-0607288e1383): NHS England
- [NHS National Framework Agreement for the Supply of Lanadelumab](/contracts/ocds-b5fd17-9389e1ff-d0d5-4000-83f2-4a38cf241d80): NHS England

## Source

[View the original notice on Contracts Finder](https://www.contractsfinder.service.gov.uk/Notice/7400eba6-8e62-4241-879e-a0c574ef4408-229021)